{"id":"W2918407168","doi":"10.1016/s2213-8587(19)30066-x","title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":367,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Manitoba; Mount Sinai Hospital","funders":"Novo Nordisk","keywords":"Semaglutide; Medicine; Type 2 diabetes; Placebo; Dulaglutide; Internal medicine; Diabetes mellitus; Randomized controlled trial; Concomitant; Clinical trial; Exenatide; Liraglutide; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001573701,0.002622046,0.006065466,0.0006923612,0.0005534574,0.001854274,0.001338225,0.002812775,0.01131319],"category_scores_gemma":[0.001573313,0.001068529,0.003265245,0.0006862335,0.001686237,0.00193733,0.0006896,0.004491434,0.001981892],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009331462,"about_ca_system_score_gemma":0.0008720388,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001914065,"about_ca_topic_score_gemma":0.003095519,"domain_scores_codex":[0.999359,0.0002531699,0.00005412371,0.0001593046,0.0000529539,0.0001215956],"domain_scores_gemma":[0.9993101,0.0001931544,0.000138991,0.00006735513,0.00004492266,0.0002454827],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9929526,0.001490924,0.0001226563,0.0004601399,0.0006279041,0.00002052793,0.00001620779,0.00007770721,0.0005782304,0.0000420295,0.0002924894,0.003318453],"study_design_scores_gemma":[0.9815074,0.01693021,0.0005489708,0.00003414875,0.0004873594,0.00001145219,0.00001557425,0.0001103452,0.00008008965,0.00005614691,0.0002094397,0.000008959428],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9716222,0.01400968,0.0008860402,0.001162618,0.002610229,0.003300334,0.002188197,0.0004218743,0.003798803],"genre_scores_gemma":[0.9750205,0.00840567,0.001458626,0.001862808,0.001397076,0.003235357,0.001793895,0.00007864324,0.006747459],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01131319,"threshold_uncertainty_score":0.03784645,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0164886080544158,"score_gpt":0.2803438125386376,"score_spread":0.2638552044842218,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}